GT-001 / Pentixapharm - LARVOL DELTA

GT-001 – anti-Lewis Y antibody with superior fine-specificity as candidate for ADC development (CIMT 2022) - "Due to the superior fine-specificity, GT-001 shows no/reduced binding of healthy leukocytes potentially reducing side effects as observed for BR96 in the clinic. The strong target binding and internalization properties combined with reduced off-target reactivity make GT-001 an ideal candidate for ADC development."

Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • CD74

Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire) - “Glycotope GmbH…announced it is presenting new data at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting…The data presented at SITC underlines our long-standing expertise in the generation, evaluation and pre-clinical development of highly novel antibodies targeting cancer indications. GT-00A x IL15, a TA-MUC1-targeting IL-15 fusion antibody is one of the first tumor-targeted immuno-cytokines. The preclinical data showed that our IL-15 immuno-cytokine has the potential to significantly outperform non-targeted IL-15 immuno-cytokines offering a highly needed alternative in the treatment of several solid-tumor indications. The data for GT-001, a Lewis Y targeting antibody, demonstrated superior specificity compared to previously developed anti-Lewis Y antibodies with the potential of improved efficacy and reduced side effects.”

Preclinical • Oncology

GT-001 - anti-Lewis Y antibody with superior fine-specificity and reduced off-target binding (SITC 2021) - "Due to the superior fine-specificity, GT-001 shows no/reduced binding of healthy leukocytes potentially reducing side effects as observed for BR96 in the clinic. Its strong target binding and internalization properties make GT-001 an ideal candidate for ADC development."

Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • CD74